I believe that if the hcv phase III trial proves to be succesfull the stock will be in double digits(!). Not that a surprise if you think about it - double digits means over $500M market cap which isn't unusual today for a biotech with a good drug on the western market.
If you're looking into other smallcap companies to increase portfolio diversification then you are invited to snoof around GILT (hitech - you'll enjoy the soap opera saga (buyout offer that went wrong and went to court) in their msg board ;-) bring some beverage and snacks and take an hour or two, :-) LOL), AMPL(energy monopoly), FORTY (holding company of SPNS & MGIC - hitech). Enjoy. :-)
From an earlier post - DNA has a capitalization ratio of about 7 times sales (after allowing for cash) while SCLN is at about 1. So we should already be at least $6 to $7 per share.
I attribute the underperformance to our history and lack of credibility with the street or with anyone for that matter. Friedhelm has a tough row to hole. Once, SCLN regains confidence from investors we should go higher than $3.50. Hopefully that will be sooner than later. With - If - good trial news this quarter, we will be fine.
i'm not doing that. just presenting facts. i originally bought this at 2.38 and trying to average down. there balance sheet looks good. i'm sorry your a "1 stock guy". my stocks as everyone else's are down many percentage points. fortunatly 65% of my $ are out of the market. are any other shareholders out there other than "one stock" disgruntaled investor !!!!!!!!!!!!!!!!!